Strategic partnerships SIGA is actively expanding through collaborations and exclusive licenses, for example with Vanderbilt University for poxvirus monoclonal antibodies, presenting a direct entry point for co-development, licensing deals, and joint commercialization opportunities.

PEP and prophylaxis Ongoing development of Post-exposure Prophylaxis indications for oral TPOXX in partnership with defense and federal programs suggests demand for prophylactic solutions and related services, creating potential upsell in MDR TB, orthopoxvirus, and emerging infectious disease portfolios.

Defense and gov funding Significant government collaboration and development funding with JPEO-CBRND and multi-million contracts indicate opportunities to align sales efforts with defense and federal health programs seeking innovative therapeutics and rapid deployment capabilities.

Therapeutic leadership SIGA focuses on best-in-class treatments for high unmet medical needs like smallpox and mpox, signaling a premium market position where specialized contract manufacturing, regulatory support, and clinical development services could be attractive to customers seeking advanced antivirals.

Financial readiness Robust revenue range and substantial funding indicate capacity for expanded R&D collaborations, milestone-based partnerships, and co-development agreements with biotech firms looking to leverage SIGA’s antiviral platform and commercialization potential.